LEO Pharma A/S, a global leader in medical dermatology, today presented late-breaking data showcasing responses in a subgroup of patients from the DELTA 1 and 2 trials at the 83 rd American Academy of ...

Alongside this presentation, new systemic exposure data has also been shared for delgocitinib cream at the meeting. 2 "The data unveiled today further contributes to LEO Pharma’s ever-growing ...

1 Separate data presented at the American Academy of Dermatology (AAD) 2025 Annual Meeting evaluated systemic exposure in patients following high use of delgocitinib cream to treat moderate to severe ...

A new survey commissioned by Leo Pharma confirms there’s plenty of room in the market for its chronic hand eczema treatment ...

LEO’s topical cream formulation of the pan-JAK inhibitor proved to be more effective than oral therapy alitretinoin in the DELTA FORCE study, which involved adults with moderate to severe CHE.